Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone

Germanidis, G.Marcellin, P.Lau, G.Bonino, F.Farci, P.Hadziyannis, S.Jin, R.Yao, G.B.Piratvisuth, T.Yurdaydın, C.Diago, M.Lai, M.Y.Popescu, M.Pluck, N.2022-11-172022-11-172004-10Germanidis, G. vd. (2004). “Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone”. Hepatology, 40(4), Supplement 1, 653A-653A.0270-9139http://hdl.handle.net/11452/29471Bu çalışma, 29 Ekim-02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’da düzenlenen 55. Annual Meeting of the American- Association for the Study of Liver Diseases (AASLD)’de bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology and hepatologyProfound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) aloneMeeting Abstract000224102101133653A653A404, Supplement 1Gastroenterology and hepatology